Key Takeaways CYBR's subscription ARR grew 65% year over year to $1.03B, now 85% of total ARR in Q1 FY25. Cross-selling wins like PKI and Venafi deals drove larger, stickier subscription contracts. Our model projects subscription ARR to rise 26% in 2025 as multi-solution adoption gains momentum.CyberArk (CYBR) reported strong subscription growth in the first quarter of fiscal 2025. Subscription annual recurring revenues (ARR) crossed $1.03 billion, up 65% from a year ago. Net new subscription ARR was $51 ...

WISeKey Shareholders Approved All Agenda Items of the 2025 Annual General Meeting Geneva, Switzerland, June 30, 2025 –WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announces that its shareholders approved all items on the agenda of WISeKey’s 2025 Annual General Meeting held on June 27, 2025. Shareholders of WISeKey approved all proposals submitted by the Board of Directors, including the following: The Annual Repor ...

Geneva, Switzerland, June 26, 2025 (GLOBE NEWSWIRE) -- SEALSQ’s unique value proposition integrates PKI with Quantum-Resistant Cryptography and Post-Quantum Secure Hardware SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced expanded capabilities to support the rapidly evolving Internet of Medical Things (IoMT) landscape. SEALSQ’s technologies provide essential s ...

DELTA, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) -- WestBond Enterprises Corporation (TSX-V: WBE) has posted a loss of $52,380 for the year ended March 31, 2025 ($210,683 loss for the year ended March 31, 2024). The value ascribed to stock options granted during the year contributed to this small loss. Sales increased 4.9% to $9,673,002 this year compared to $9,219,948 for the year ended March 31, 2024. The increase in revenue is the result of an increase in sales of wipe products and air-laid napkin ...

Imagine that you have the power to learn any skills at any point of time without any barriers, without any limits. So how would it be. Today I'm going to talk about artificial intelligence. That is my area of expertise and I love to talk about it.I love to explore and see how we can together make AI a better use case, a better tool for every one of us. So imagine that anyone can learn the skills at any point of time without barriers, without limits. That's the world I want to build.My name is Shubhham Tumbr ...

Core Insights - AbbVie has established a significant oncology franchise, expanding from blood cancer drugs to include therapies for solid tumors, with five oncology products now available [1][7] - The oncology segment contributed over 12% to AbbVie's total revenues in Q1 2025, with expectations for Emrelis, its first internally developed lung cancer drug, to start contributing in Q3 2025 [1][2][7] Company Strategy - AbbVie is pursuing both organic and inorganic growth strategies, with recent additions to its oncology portfolio coming from acquisitions and collaborations, while Emrelis represents an internal development [2] - The company has a diverse pipeline of promising therapies, including etentamig for multiple myeloma and Temab-A for colorectal and gastroesophageal cancers, indicating a strong focus on expanding its oncology offerings [3][7] Competitive Landscape - Major competitors in the oncology space include AstraZeneca, Merck, and Pfizer, with AstraZeneca's oncology sales accounting for nearly 41% of its total revenues and growing by 13% in Q1 2025 [4] - Merck's Keytruda accounted for over 46% of its total revenues in Q1 2025, while Pfizer's oncology revenues grew by 7%, making up over 27% of its total revenues [5] Financial Performance - AbbVie shares have outperformed the industry year to date, although the company's valuation is not considered cheap, trading at a P/E ratio of 13.99 compared to the industry average of 14.81 [6][9] - The Zacks Consensus Estimate for AbbVie's earnings has increased for both 2025 and 2026, indicating positive market sentiment [10]

Core Insights - BrightSpring Health Services' specialty pharmacy, Onco360®, has been selected as the national pharmacy partner for newly approved therapies targeting advanced cancers and rare genetic disorders [1][3]. Company Overview - BrightSpring Health Services offers integrated home- and community-based pharmacy and health solutions for complex populations, serving over 400,000 customers daily across all 50 states [4]. - Onco360® is a leading independent oncology pharmacy founded in 2003, focusing on the specialized needs of oncologists, patients, and healthcare providers [5]. New Therapy Partnerships - Onco360® will provide access, education, data, and expert support for innovative treatments for advanced ovarian and lung cancers, as well as neurofibromatosis type 1 [2][3]. - The therapies include GOMEKLI™ for neurofibromatosis type 1, AVMAPKI™ FAKZYNJA™ CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, and IBTROZI™ for ROS1-positive non-small cell lung cancer [6].

Key Takeaways ABBV's Venclexta plus azacitidine missed the survival goal in the phase III VERONA study for MDS. The trial showed a hazard ratio of 0.908, indicating no significant survival benefit over control. ABBV continues building its oncology pipeline, now including five marketed therapies and late-stage assets.AbbVie (ABBV) announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study evaluated a combination therapy involving its blockbuster cancer drug ...

The new design system transforms the appearance of a Mac window, altering the window shape and framing its key structural regions in glass. One of those regions is the toolbar. In the new design system, toolbar elements are placed on a glass material, and the entire toolbar appears to float above the content, enhancing the sense of hierarchy within the window.The glass also brings controls together in logical groups. Since they all represent singular actions, AppKit automatically groups multiple toolbar but ...

Key Takeaways Suzano will hold 51% of a $3.4B tissue joint venture with Kimberly-Clark, transaction to close in mid-2026. The JV spans 22 plants across 14 countries with 1M-ton annual output and $3.3B in 2024 net sales. Suzano will pay $1.734B in cash at closing, aligning with its strategy of scalable, efficient growth.Suzano S.A. (SUZ) and Kimberly-Clark Corporation (KMB) announced that they would create a $3.4-billion joint venture that will manufacture consumer and professional tissue products. Suzano ...